Table 1.
Demographic, clinical, and procedural characteristics of the study populations based on postoperative Atrial Fibrillation Risk Index.
| Predictor | No postoperative AF (n=32) | Postoperative AF (n=13) | P-value* |
|---|---|---|---|
| Age, y | 55.81±9.48 | 66±12.1 | 0.0118 |
|
| |||
| Medical History | |||
| Atrial fibrillation | 0 (0) | 0 (0) | |
| Chronic obstructive pulmonary disease | 2 (6.25) | 2 (15.4) | 0.344 |
|
| |||
| Concurrent valve surgery | 0 (0) | 0 (0) | |
|
| |||
| Withdrawal of Postoperative Treatment | |||
| Beta-blocker | 0 (0) | 0 (0) | |
| ACE inhibitor | 18 (56.25) | 7 (53.9) | 0.883 |
|
| |||
| Beta-blocker Treatment | |||
| Preoperative and postoperative | 32 (100) | 11 (84.6) | 0.0788 |
| Postoperative | 32 (100) | 13 (100) | |
|
| |||
| Preoperative and Postoperative ACE Inhibitor Treatment | 5 (15.63) | 0 (0) | 0.301 |
|
| |||
| Preoperative and Postoperative Statin Treatment | 26 (81.25) | 8 (61.5) | 0.171 |
|
| |||
| Postoperative Treatment | |||
| Potassium supplementation | 30 (93.75) | 12 (92.3) | 0.861 |
| Non-steroidal anti-inflammatory drugs | 10 (31.25) | 3 (23.1) | 0.585 |
Continuous variables are presented as means ± standard deviation, and categorical variables as percent frequencies. ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation.
*
P-values were derived from the Wald tests, or from Fisher’s Exact Test as appropriate.